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Main Text: Introduction
Monoclonal antibodies (mAbs) have revolutionized the medical field, allowing the treatment of diseases, which were previously deemed incurable (1) . For mAb discovery, screening and production, hybridoma technology has been widely used since its introduction in 1975 (2) . Hybridomas are immortal cell lines capable of secreting large quantities of mAbs and have been proven to be essential for the development of new antibody-based therapies. Over the past decades, a large number of hybridomas have been generated, validated and made available, including hybridomas used for preclinical research. Besides the antigen specificity, the mAb format and isotype are important determinants for performance in preclinical models. However, as the mAb heavy chain sequence is genetically fixed in the hybridoma, the possibilities to adjust antibody format and functionality without compromising target specificity are limited. Typically, genetically engineered mAbs are produced using recombinant technology. This requires sequencing of the variable domains, cloning of these variable domain sequences into the plasmids with the appropriate backbone, and expression of these plasmids in transient systems. These procedures are often time-consuming, challenging and expensive and therefore often outsourced to specialized contract research companies, hampering academic earlystage antibody development and preclinical application.
The importance of the antigen binding variable regions is apparent. However, the constant domains which form the fragment crystallisable (Fc) domain are also central to the therapeutic efficacy of mAbs. Numerous studies have demonstrated that therapeutic efficacy of certain mAbs depends on the Fc domain and their engagement with specific Fc receptors (FcRs) (3) (4) (5) (6) (7) (8) . In a recent example, Vargas et al. demonstrated that anti-CTLA-4 immunotherapeutic working mechanism revolves around depletion of regulatory T-cells in the tumor microenvironment, utilizing Fc variants of the same antibody (4) . The authors postulated that this could explain why cancer patients treated with ipilimumab, a human IgG1 CTLA-4 targeting mAb, greatly benefit from an activating FcγRIIIapolymorphism which increases affinity for human IgG1 (4) . This highlights the central role the Fc plays in antibody-based therapeutics, and emphasizes the importance of evaluating novel mAbs in different Fc formats in early development.
The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 (CRISPRassociated Protein 09) targeted genome editing technology opened up a plethora of exciting opportunities for gene therapy, immunotherapy, and bioengineering (9) . Recently, CRISPR-Cas9 has been used to modulate mAb expression in hybridomas: Cheong et al. forced class-switch recombination in IgM producing hybridomas to downstream immunoglobulin classes via deletion of the natural S regions, and induced Fab' fragment production by deletion of the entire Fc region (10) .
Pogson et al. generated a hybridoma platform in which the variable domains can be substituted (11) , and affinity maturation can be simulated via homology directed mutagenesis with single stranded oligos (12) . Khoshnejad et al. engineered a hybridoma to introduce a sortase recognition motif (sortag) (13) on the C-terminus of the constant heavy chain domain 3 (CH3) for site-specific chemoenzymatic antibody modification purposes (14) . However, to date no platform has been described for versatile and effective Fc substitution in hybridomas with constant domains from foreign species, isotypes or formats.
Here, we demonstrate genetic engineering of hybridomas via a one-step CRISPR/ Homology Directed Repair (HDR)-based strategy enabling rapid generation of recombinant hybridomas secreting mAbs in the Fc format of choice with the freedom to install preferred tags or mutations. We generated hybridomas producing Fab' fragments, c-terminally equipped with a sortag and a histag for sitespecific chemoenzymatic modification and purification purposes. Furthermore, we incorporated novel constant domains upstream of the native constant region to generate hybridomas which secrete chimeric antibodies with the isotype and species of choice, as well as Fc mutant mAbs without compromising antigen specificity. The engineered antibodies are easily isolated from the hybridoma supernatant and display their expected biochemical and immunological characteristics, both in vitro and in vivo. Because we target the constant domains of the immunoglobulin locus, our CRISPR/HDR method is adaptable to hybridomas from any species or isotype. We believe that this versatile platform will empower preclinical antibody research by opening up antibody engineering for the entire scientific community.
Results

Generation of recombinant hybridomas producing sortagable Fab' fragments
Monovalent Fab' fragments consist of a shortened heavy chain and light chain and, due to their smaller size, have certain advantages over their parental mAbs. Fab' fragments have better tissue penetration, are not susceptible to Fc-mediated uptake and do not exert immune effector functions. Therefore, Fab' fragments have been used for treatment of certain autoimmune diseases (15) , targeting of different payloads (16, 17) , and generation of bispecific antibodies (18) . The conventional method to obtain Fab' fragments is papain cleavage of the parental mAb followed by purification of the Fab' fragment. However, this does not allow for installment of useful tags or mutations. Alternatively, one could use recombinant production in transient systems, however this requires prior knowledge of the variable heavy and light chain sequence, optimization of the transient system, and multiple rounds of production. Rapid conversion of hybridomas into Fab' secreting cell lines via CRISPR/HDR engineering represents a simple and cost-effective alternative to obtain inexhaustible source of Fab' fragment with the freedom, to introduce mutations or tags of choice.
To obtain Fab' secreting hybridomas via CRISPR/HDR we selected the hybridoma clone NLDC-145 (19) as a first target ( Fig. 1A,B ). This hybridoma secretes mAbs of the rat IgG2a (rIgG2a) isotype, and is specific for murine DEC205. This endocytic receptor is abundantly expressed by dendritic cells, and employed as a target in various vaccination strategies (20, 21) . To target the heavy chain locus of NLDC-145, we used an optimized guide RNA (gRNA-H) which directs Cas9 to the rIgG2a hinge region to generate double stranded breaks ( Fig. S1) . To repair the double stranded break, we designed an HDR donor construct (Table S1 ) that inserts a sortag and histag directly upstream of the cysteine involved in heavy chain dimer formation. Furthermore, we included a blasticidin-S deaminase (Bsr) gene to select cells, which successfully integrated the construct. We electroporated NLDC-145 hybridoma cells with the HDR Fab' donor construct and Cas9 PX459 vector containing gRNA-H, and subsequently applied blasticidin pressure. After blasticidin selection, we assessed knock-in of the donor construct by genomic PCR with a forward primer that hybridizes upstream of the 5' homologous arm, and a reverse primer specific for the HDR construct. PCR products of the expected size (~1600bp) were exclusively observed for the transfected population, indicating integration of the donor construct in the correct genomic location (Fig. 1C) . After one week, we performed a limiting dilution to obtain monoclonal cell suspensions. We used the supernatant of these monoclonal cell suspensions to determine antigen specificity and phenotype of the secreted product.
We first stained JAWSII, a DEC205 expressing cell line, with the supernatant from each clone and performed a subsequent secondary staining for the histag and rIgG2a heavy chain. Flow cytometry analysis revealed that a large fraction of monoclonal hybridomas was successfully engineered ( Fig.   1D ), as we observed DEC205 binding constructs harboring a histag in the supernatant of 47 out of 76 clones. In contrast, only a single cell suspension (clone 48) still produced the mAb DEC205 of the rat IgG2a isotype. To validate the flow cytometry results, we performed a Western Blot for the heavy and light chain on the supernatant of clones 47 to 52 (Fig. 1E) . The four clones that were histag pos rIgG2a neg by flow cytometric analysis, indeed secreted a shortened heavy chain that was histag positive, confirming production of histagged Fab' fragments by these clones. Clone 48 (histag neg , rIgG2a pos ) retained its expression of the rat heavy chain, while for clone 47 (histag neg , rIgG2a neg ) only rat light chain could be observed.
For further characterization of the secreted Fab'DEC205-sortag-histag (hereafter Fab'DEC205srt) we selected one clone (hereafter Fab' hybridoma) of which the heavy chain sequence was validated by Sanger sequencing. After expansion of the Fab' hybridoma, Fab'DEC205srt was easily isolated from the supernatant with high purity via Ni-NTA gravity flow. To assess whether the Fab'DEC205srt retained antigen specificity, we performed a competitive binding assay. We used a fixed concentration of fluorescently labelled parental NLDC-145 mAb in combination with increasing concentrations of Fab'DEC205srt, unlabeled NLDC-145 mAb, and an isotype control antibody ( Fig.   1F ). Contrary to the isotype control, Fab'DEC205srt and NLDC-145 mAb competed for DEC205 binding with the fluorescent mAb in a dose dependent manner, indicating that the CRISPR engineered Fab'srt binds the same epitope and that antigen specificity is not affected by our CRISPR/HDR approach. The lower EC50 of the Fab' fragment compared to NLDC-145 is in line with the difference in avidity between monovalent Fab' and bivalent mAb.
In contrast to conventional proteolytic cleavage to obtain Fab' fragments, CRISPR/HDR engineering allows the inclusion of various tags. Besides the histag to facilitate purification, we introduced a c-terminal sortag (LPETGG) for chemoenzymatic conjugation using the sortase enzyme ( Fig. S2A) . Unlike classical stochastic chemical conjugation strategies, the sortag facilitates sitespecific coupling of cargo to mAbs without the danger of compromising the n-terminal binding region and results in a homogeneous final product (13, 22) . To show sortag functionality of Fab'DEC205-srt we used a fluorescently labelled sortase substrate probe (GGGCK(FAM), Fig. S2B ) and (fluorescent) SDS-PAGE analysis. When Fab'DEC205-srt was exposed to 3M sortase (a mutated sortase for higher conversion efficacy) (23) alone, the heavy chain c-terminal sortag-histag was hydrolysed resulting in a lower molecular weight heavy chain product ( Fig. 1G, Fig S2C) . However, in the presence of the fluorescent sortase probe the reaction gave quantitative conversion to a fluorescently labelled Fab'DEC205 heavy chain, proving functionality of the sortase recognition motif introduced using our CRISPR/HDR approach.
After successfully converting NLDC-145 to recombinant hybridomas producing fully functional Fab'DEC205-srt, we applied the same strategy to other hybridomas of interest in the field of immuno-oncology. We generated Fab' hybridomas against murine CD40 (clone FGK45.5), programmed death 1 (PD-1, clone RMP-14) and PD-L1 (clone MIH5). The resulting Fab' fragments were purified and site-specifically modified to obtain fluorescently labelled Fab' fragments ( Fig S2C) .
Taken together, we demonstrate that our CRISPR/HDR Fab' hybridoma engineering approach is effective in generating an inexhaustible source of Fab' fragments equipped with affinity and chemoenzymatic tags with retention of antigen specificity.
Isotype panel generation via CRISPR/HDR engineering of hybridomas
Encouraged by the success of our one-step CRISPR/HDR strategy to generate Fab' hybridomas, we continued by further expanding the platform and engineered hybridomas to secrete a diverse set of Fc variants of the same antibody. We designed a CRISPR/HDR genetrap knock-in approach which installs Fc constant domains (heavy chain constant domain 1 (CH1), hinge, CH2 and CH3, sortag, histag, Bsr) upstream of the native rat domains ( Fig. 2A,B) . To force linkage of the genetically engineered foreign CH domains to the native heavy chain variable (VH) domains an artificial splice acceptor was incorporated directly upstream of the new Fc.
To test our method we genetically engineered the hybridoma MIH5, which secretes rIgG2a mAbs targeting mouse immune checkpoint PD-L1, to produce chimeric murine IgG1 (mIgG1), mIgG2a, mIgG2b, mIgG3 and mIgA antibodies. Furthermore, we included a mutant mIgG2a isotype with the amino acid substitutions L234A/L235A/N297A (mIgG2a silent ), which is described to have reduced affinity for murine FcγRs (24) . After selection of an optimal sgRNA targeting a PAM sequence 100bp upstream of the rIgG2a CH1 (gRNA-ISO), MIH5 cells were co-transfected with a Cas9 vector containing gRNA-ISO and the panel of isotype HDR donor constructs (Table S2 ). Next, we assessed on-target knock-in integration of blasticidin selected cells by genomic PCR. Analysis showed the presence of PCR products of expected size (~2600bp, Fig. 2C ). Monoclonal cell lines were obtained and supernatant was used for flow cytometric screening of the secreted mAbs. CT26 (a mouse colon carcinoma cell line) cells were stimulated with IFN-γ to induce upregulation of PD-L1 before incubation with the supernatants, followed by staining with secondary antibodies for each specific isotype (data not shown). Multiple chimeric clones that expressed the genetically engineered isotypes were identified. We selected a single clone for each isotype and validated the correct knock-in of the isotype of choice in the IgH locus by sequencing. Detailed flow cytometry analysis of the mAbs produced by the selected clones using IFN-γ stimulated CT26 cells revealed that the engineered chimeric mAbs were positive for their respective murine isotypes as well as histag, but not for the native rIgG2a isotype (Fig. 2D) . To validate antigen specificity of our MIH5 derived engineered antibodies, PD-L1 knock out CT26 cells (CT26 PD-L1 KO (25)) were exposed to the purified mAbs.
Contrary to the WT CT26 cells, IFN-γ stimulated CT26 PD-L1 KO cells were not stained by our mAbs, proving retention of target specificity ( Fig. S3A) . Western blot analysis of the purified antibodies confirmed substitution of the native rat heavy chain by the genetically introduced mouse heavy chain on protein level ( Fig. S3B) . Notably, if the native splice acceptor adjacent to the CH1 of the rIgG2a is kept in place after CRISPR/HDR, we observed native rIgG2a isotype in the supernatant of chimeric hybridomas as well as in Ni-NTA gravity flow purified proteins, suggesting rat-mouse heavy chain heterodimer mAb formation. We postulated that in these cases, gene elements downstream of the inserted murine heavy chain could still be transcribed due to incomplete transcription termination, facilitating splicing of the VH region to the native rIgG2a isotype. Removal of the native splice acceptor in the HDR donor construct completely abrogated the production of the rat IgG2a isotype ( Fig. S3C) . We equipped all our engineered chimeric mAbs with a c-terminal sortag to facilitate chemoenzymatic functionalization. To confirm functionality of c-terminal sortag we performed a sortase ligation with the fluorescent peptide GGGCK(FAM) ( Fig. 2E, Fig. S4 ). Indeed, fluorescent SDS-PAGE analysis showed that all the heavy chains from chimeric mAbs were fluorescently tagged, whereas the parental MIH5 antibody was not. Modification of the isotype using our CRISPR/HDR genomic engineering approach is not restricted to the MIH5 hybridoma, as we were able to successfully perform the same strategy on the NLDC-145 hybridoma and obtained a panel of DEC-205 isotype variant mAbs ( Fig. S5) .
We extended the molecular characterization of our engineered mAbs by high-resolution native mass spectrometry analysis of the mIgG2a silent . Asparagine (N) on position 297 (N297) is a conserved glycosylation site and is one of the major determinants of FcγR engagement, and hence of therapeutic efficacy of certain mAbs. In mIgG2a silent , the N297A amino acid substitution is introduced, rendering it Fc-silent (24) . To validate the absence of glycans in this engineered mutant, we treated MIH5 WT and mIgG2a silent with the glycosidase PNGase F to remove existing glycans. Subsequently, we performed high resolution native mass spectrometry on treated and untreated samples to assess whether glycans were removed. For the WT samples clear shifts in protein mass were observed, with a leading loss of 2889.6 Da, corresponding to the loss of two glycans (G0F: asialo-agalacto-corefucosylated biantennary complex-type N-glycan, theoretical mass 2890 Da per mAb, Fig. 3A) . In contrast, no difference in mass between the PNGase F treated and untreated samples of mIgG2a silent could be measured, indicating the absence of glycans ( Fig. 3B) . Native mass spectrometry analysis of MIH5 mIgG2a variant before and after PNGase F treatment showed a mass difference of 2889.2 Da, corresponding to two G0F glycans, analogous to the WT MIH5 mAb (Fig. S6) .
Our data demonstrates the effective one-step generation of stable hybridomas producing Fc engineered chimeric mAbs using our CRISPR/HDR approach. These mAbs retain their antigen specificity and the addition of affinity and chemoenzymatic tags adds an additional layer of flexibility and utility.
Biochemical and functional characterization of the engineered antibodies
Having established and validated our hybridoma CRISPR/HDR genomic engineering approach we set out to characterize the functional properties of our isotype-switched mAbs. We first evaluated the binding affinities of our panel of chimeric anti-mouse PD-L1 mAbs for immobilized mFcγRIa, mFcγRIIb and mFcγRIV on a multiplex biosensor via surface plasmon resonance (SPR).
We monitored the association and dissociation over time ( Fig. 4A ) and generated affinity plots to calculate the dissociation constants (K D ) for each receptor concentration. Subsequently, these were interpolated to calculate the affinity of each antibody at receptor concentration giving R max =500, as described before (26) (Fig. 4B) . The obtained affinities of mIgG1, mIgG2a and mIgG2b for the FcγRs fall well within the range of previously reported K D values for recombinantly produced isotypes (Table S3 ) (26) . In summary, mIgG1 did not bind mFcγRI and mFcγRIV, but binds to mFcγRIIb;
mIgG2a displayed binding to all tested mFcγRs with highest affinity for mFcγRI, followed by mFcγRIV and mFcγRIIb; mIgG2b binds to mFcγRIIb and mFcγRIV, with stronger affinity for the latter. mIgA and the Fc-silent mutant mIgG2a silent did not show affinity for any of the mFcγRs. The WT rIgG2a displays a FcγR engagement profile similar to the one of mIgG1, binding to the FcγRIIb, but not to FcγRI and FcγRIV. Due to protein aggregation, a characteristic previously reported for mIgG3 (27, 28) , we were not able to determine the K D values for this isotype variant. Based on the differential affinity for activating and inhibiting receptors reported here, we predicted the capacity of CRISPR engineered mAbs to evoke antibody dependent cellular cytotoxicity (ADCC) (Fig. 4C) , as others have done in the past (8) .
To conclude the characterization of the generated istoype variants we assessed their capacity to induce ADCC in vitro and in vivo. In vitro, we labelled MC38 (murine colon adenocarcinoma) cells with chromium-51, opsonized these with MIH5 Fc variants, and added whole blood from C57BL/6 mice for four hours. To assess specific lysis we measured the chromium-51 release and used an aspecfic mAb (AZN-D1) as a baseline (Fig. 5A) . In vivo, we assessed the ability of MIH5 Fc variants to deplete B-cells (Fig. 5B) . We labelled isolated splenic B-cells from C57BL/6 mice with Far Red tracer dye and opsonized these with mIgG2a, mIgG2b or mIgA. Simultaneously, we used mIgG2a silent to opsonize splenic B-cells labelled with Violet Blue tracer dye. Subsequently, we mixed the populations in equal ratio and injected these intravenously into LPS-primed C57BL/6 mice. After 24 hours, we sacrificed the mice and isolated the spleens to determine the ratio between the Violet blue and Far red population to assess relative B-cell depletion via flow cytometry (Fig. 5C, Fig S7) . Both in vitro and in vivo assays yielded similar results; mouse IgG2a displayed the strongest capacity to induce Fc mediated killing of target cells, followed by mIgG2b, which is in line with literature and the observed FcyR binding affinities ( Fig. 4A-C) . Neither wildtype rIgG2a, nor its CRISPR engineered variants mIgG1, mIgG3, mIgA and mIgG2a silent were able to mediate specific killing or depletion. As mIgG3, mIgG2a silent and mIgA do not interact with murine Fc receptors, these are unable to mediate ADCC.
The lack of effect for rIgG2a and mIgG1 Fc variants can be explained by their ability to bind only a single activating FcyR (FcyRIII), whereas mIgG2a and mIgG2b bind respectively three and two activating FcγRs. Taken together, our in vitro and in vivo data indicate that chimeric and mutant mAbs through hybridoma engineering approach exhibit the same biochemical and immune effector characteristics as their natural and recombinantly produced counterparts.
Discussion
Here we report the development of a versatile platform for easy and rapid generation of panels of Fc engineered antibodies starting from their parental hybridomas. Using a one-step CRISPR/HDR approach we obtained hybridomas producing either monovalent Fab' fragments, Fc isotype variants from a foreign species (from rat-anti-mouse to mouse-anti-mouse), and Fc silent mutants without effector functions, within a period of 21 days. Additionally, our method allows incorporation of useful protein tags for purification and site-specific conjugation purposes. Extensive characterization of the produced antibodies revealed that target specificity is uncompromised, and that the CRISPR/HDR engineered chimeric antibodies display their intrinsic Fc-effector functions. Currently, most researchers rely mainly on recombinant production methods to evaluate monoclonal antibodies in different Fc formats. To do so, the variable heavy chain and light chain need to be sequenced, cloned into the appropriate backbones and transfected multiple times into mammalian expression systems to obtain sufficient antibody yields. This process often requires extensive optimization, expertise, knowledge and dedicated resources, not available in most laboratories. In contrast, the CRISPR/HDR strategy outlined here, offers a simple alternative approach requiring a single electroporation step to obtain an unlimited source of target antibody in the isotype format of choice.
Other investigators also described approaches to modulate heavy chain loci in hybridomas via genomic engineering. However, these approaches are either restricted in their engineering capabilities or require multiple sequential genome editing events. We demonstrate, for the first time, the ability to modulate the antibody isotype in hybridomas to a panel ranging from the activating Fc variant mIgG2a, to the Fc-silent mIgG2a silent . It is widely recognized that mAb isotype is of major importance for the outcome of antibody-based therapies, especially in the field of cancer immunotherapy. Various studies have shown that the therapeutic efficacy of mAbs directed against immune checkpoints such as CTLA-4, CD25, PD-L1, GITR, and OX-40 depends on their isotype (4, 5, (30) (31) (32) . This is mainly due to the interaction of the Fc-region with different components of the immune system, such as FcRs on the surface of immune cells and the C1q protein of the complement system. Substantial efforts have been made to modulate Fc affinity for these different components making use of amino acid substitutions in the Fc-region. This has led to a wide range of described mutants which can be used to increase affinity for activating or inhibitory FcRs (33) (34) (35) , ablate Fc-effector functions (36) , or recruit complement (37, 38) . Moreover, amino acid substitutions can also be used to control antibody half-life (39) or to construct bispecific antibodies (40, 41) . All of these mutant Fc variants can be implemented in our versatile single step CRISPR/HDR platform.
This method is accessible for any laboratory capable of hybridoma cell line culturing, thus providing a molecular toolbox for repurposing the wealth of established hybridoma cell lines available. Since many hybridoma products are extensively used in preclinical in vivo studies, our method will empower preclinical antibody research by enabling screening of large panels of antibody variants early on in therapeutic antibody development. Moreover, the freedom to add affinity tags and amino acid recognition sequences for chemoenzymatic modification adds an additional layer of flexibility and utility. The ability to site-specifically functionalize the engineered antibody products will find application in the fields of biomolecular engineering, chemical biology, antibody-drug conjugates, multimodal imaging and nanomedicine. We are convinced that this method will open up antibody engineering for the entire scientific community.
Materials and Methods
General culture conditions.
The following hybridoma clones were genetically engineered for expression of Fab fragments or 
Hybridoma nucleofection with donor constructs and CRISPR-Cas9
Nucleofection of the HDR template and CRISPR-Cas9 vectors was performed with SF Cell Line 4D-Nucleofection X Kit L (Lonza, V4XC-2024). Before nucleofection hybridoma cells were assessed for viability and centrifuged (90g, 5 minutes), resuspended in PBS/1% FBS and centrifuged again (90g, 5 minutes). One million cells were resuspended in SF medium with 1 μg of HDR template and 1 μg of CRISPR-Cas9 vectors or 2 μg of GFP vector (control) and transferred to cuvettes for nucleofection with the 4D-Nucleofection System from Lonza (Program SF, CQ-104). Transfected cells were transferred to a 6-well plate in 4 mL of complete medium. The following day the cells were transferred to a 10 cm petridish in 10 mL of complete medium, supplemented with 10-20 μg/mL of blasticidin (Invivogen, anti-bl-05). Antibiotic pressure was sustained until GFP transfected hybridomas were dead and HDR transfections were confluent (typically between day 10-14). Cells were subsequently clonally expanded by seeding the hybridomas in 0,3 cells/well in u-bottom 96-well plates in 100 μL of complete medium. After one week, supernatant from wells with a high cell density
were obtained for further characterization.
Genomic DNA isolation, PCR and sequencing.
One week after nucleofection with HDR and targeting constructs a minimum of 10,000 cells of the surviving cell population were collected for genomic phenotyping. DNA was extracted using the genomic DNA isolate kit from Bioline (BIO52067). The DNA pellet was resuspended in ultra- Antibody production and isolation.
Engineered hybridomas selected for production were expanded in T175 flasks containing 20mL of complete medium. Once confluent, hybridomas were cultivated for another 1-10 days in RPMI-1640 supplemented with 2mM ultraglutamine, 1x AA, 50uM 2-ME, and 10% FBS. For larger antibody titers, 20 million cells were seeded in Celline Bioreactor Flasks (Argos, 900-05) and cultivated for 1 week. Antibody-containing-supernatants were separated from cells via centrifugation (90g, 5 minutes), filtered through a 20μM filter and supplemented with 10mM imidazol (Sigma-Aldrig, I2399). Subsequently the hybridoma supernatant was run over a Ni-NTA column (Qiagen, 30210). The column was subsequently washed with 10 column volumes of PBS with 25mM imidazole before antibody elution with PBS containing 250mM imidazole. Buffer exchange to PBS (for mIgG3;
300mM NaH 2 PO 4 , 50mM NaCl 2, pH 6.5) was performed via ultracentrifugation with amicon Ultra-15
Centrifugal filter units (Sigma, Z717185). Antibodies from WT hybridomas were obtained by cultivating parental hybridoma using CD Hybridoma medium (Thermofisher, 11279023) supplemented with 2mM ultraglutamine, 1x AA and 50uM 2-ME. Antibodies were purified from medium using protein G gravitrap (Sigma, 28-9852-55) according to manufacturer protocol. Antibody concentration was determined via absorption at 280nm with an extinction coefficient of 1.4. Protein purity was assessed by SDS-PAGE using SYPRO™ Ruby Protein Gel Stain (ThermoFisher, S12000).
Sortase-mediated ligation
To assess sortase-mediated conjugation a small nucleophilic peptide (GGGCK(FAM)) was Orbitrap instrument with extend mass range (EMR) as described before (42) . Intact Mass software was used for zero-charge deconvolution of the spectra to determine the antibody mass (43) .
FcγR engagement
Surface plasmon resonance measurement were performed on an IBIS MX96 (IBIS technologies) with a similar methodology as described before (26) . In short, biotinylated mouse FcγRI, FcγRIIb and FcγRIV were immobilized in duplicate, ranging from 30nM to 1nM onto a single SensEye G-streptavidin sensor. Then MIH5 Fc variants were injected over the IBIS in PBS supplemented with 0.075% Tween-80 in concentrations ranging from 0.49nM to 1000nM. K D calculation was performed by fitting a 1:1 langmuir binding model to the RU 360sec values at each antibody concentration. For consistency, these fits were performed at each receptor concentration and the final K D values were calculated by interpolating to R max =500. The measurements were performed in triplicate.
ADCC in vitro
Mouse whole blood ADCC with a 51 Cr release assay was performed as described before (44) . Predicted ADCC activity for each murine isotype variant on the basis of their differential affinity for FcγRs. 
